Patient P-01667

Synthetic patientNBL-101 · Day 104 · 65–74 · M · baseline S10Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Stable

Discontinuation risk

48%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S10
Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 52 GI-04 recommended — GI Support Protocol GI-04
Day 53 Patient accepted — Started GI-04 in the companion
Day 61 GI symptom burden −38% vs expected — GI Support Protocol GI-04
Day 61 ME-01 recommended — Monitoring Escalation ME-01
Day 62 Patient accepted — Started ME-01 in the companion
Day 65 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 67 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 46.

Primary contributors, last 14 days

Treatment adherence+6
Toxicity-5
Nutritional resilience+3
Inflammatory activity+2

What helped?

GI Support Protocol GI-04Day 52
Result: symptom burden −38%
Monitoring Escalation ME-01Day 61
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

55%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

47.5/100

stable · +1.2 vs previous 14 d

Toxicity

Blood

36.6/100

improving · -8.3 vs previous 14 d

Sleep quality

Wearable

12.4/100

improving · +0.8 vs previous 14 d

Energy level

Daily log

2.8/10

stable · +0.1 vs previous 14 d

Stress level

Daily log

6.6/10

stable · +0.1 vs previous 14 d

Steps

Wearable

3,716

stable · +25 vs previous 14 d

Adherence

Companion

55.9 %

worsening · -2.2 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading drifting · 37 from the failing basin, 50 from restoration.

Good elements to keep

GI Support Protocol GI-04
intervention · steering +58.9
Monitoring Escalation ME-01
intervention · steering +4.4
Daily walks resumed
perturbation · steering +3.3

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
Low microbial diversity
hidden · steering -7.7
IL6 high-expression variant
hidden · steering -7.3
Dietary fat load
perturbation · steering -6.1
Dietary fat load
detractor · GI +3.4 next day
Simple carbohydrates
detractor · GI +3.4 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+3.4detractor · 95%
Simple carbohydrates
+3.4detractor · 95%
Spicy / capsaicin
+3.2detractor · 91%
Alcohol
+2.9detractor · 95%
Insoluble fibre
+0.7no signal · 20%
Histamine load
+0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 23/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 51
- WearableHRV 31 ms, trending down
Autonomic recovery ↑65
- WearableResting HR 79 bpm
- Wearable3,716 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 48 and rising
- WearableSleep 5.4 h, below personal baseline

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure

Microbiome

Shannon diversity 2.8 · butyrate capacity 23/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 30 ms
Sleep: 5.5 h
Steps: 5,101
Resting HR: 80 bpm

Daily log: GI score 48, nutritional resilience 48, adherence 56.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01604	25%	S01	—	—	71
P-01386	25%	S13	—	—	70
P-01352	25%	S20	—	—	70
P-01750	25%	S16	—	—	69
P-01699	33%	S04	GI-04	improved	69
P-01508	26%	S18	—	—	68
P-01509	27%	S17	—	—	68
P-01817	26%	S14	—	—	67
P-01877	30%	S01	CR-01	improved	67
P-01629	28%	S19	—	—	66
P-01714	33%	S14	GI-04	improved	66
P-01858	34%	S14	NP-02	improved	65